Novo Says CagriSema Won't Launch in Europe for a Couple of Years
- Novo Nordisk's outgoing CFO, Karsten Munk Knudsen, told Endpoints that CagriSema will not launch in Europe for another "couple of years."
- Novo's third-quarter report says it is preparing for a US launch in early 2027, subject to regulatory approval.
💡 Points Based on public reports
A US-first, Europe-later sequence for the company's most important obesity follow-up is a notable choice when Lilly's tirzepatide is already established in European markets. The snippet doesn't say whether supply, reimbursement or regulatory timing drives it; that is the thing to find out, because the reason decides whether it is a one-region delay or a template for later launches. It is also a statement from a departing executive, so treat the timeline as indicative.
Novo won't launch CagriSema in Europe for 'a couple of years,' CFO says ↗